Edition:
United Kingdom

Rhythm Pharmaceuticals Inc (RYTM.OQ)

RYTM.OQ on NASDAQ Stock Exchange Global Market

22.19USD
20 Apr 2018
Change (% chg)

$-0.23 (-1.03%)
Prev Close
$22.42
Open
$22.24
Day's High
$22.44
Day's Low
$21.93
Volume
11,164
Avg. Vol
38,998
52-wk High
$33.80
52-wk Low
$16.89

Chart for

About

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent,... (more)

Overall

Beta: --
Market Cap(Mil.): $685.07
Shares Outstanding(Mil.): 27.13
Dividend: --
Yield (%): --

Financials

  RYTM.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.24 -- --
ROI: -- 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda

* RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME

02 Apr 2018

BRIEF-Rhythm Pharmaceuticals Reports Qtrly Loss Per Share $0.41‍​

* RHYTHM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide

* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY

04 Jan 2018

BRIEF-Rhythm Pharmaceuticals reports Q3 loss of $1.78/shr

* Rhythm Pharmaceuticals reports third quarter 2017 financial results

14 Nov 2017

Earnings vs. Estimates